RecruitingPhase 2NCT07527650

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Subjects With Type 2 Diabetes Mellitus

Sponsor

Hanmi Pharmaceutical Company Limited

Enrollment

180 participants

Start Date

May 18, 2026

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Mellitus T2DM

Summary

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called HM15275 and a drug called Placebo of HM15275 for people with t2dm and type 2 diabetes mellitus. The study is currently recruiting participants at 10 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHM15275

HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.

DRUGPlacebo of HM15275

A sterile, matching solution supplied in pre-filled syringes.

Locations(13)

Desert Clinical Research

Mesa, Arizona, United States

Charter Research

Orlando, Florida, United States

AdventHealth Translational Research Institute

Orlando, Florida, United States

Centricity Research IRT - DBA IACT Health Columbus Piedmont

Columbus, Georgia, United States

The South Bend Clinic

South Bend, Indiana, United States

Jefferson City Medical Center

Jefferson City, Missouri, United States

Clay Platte Family Medicine

Kansas City, Missouri, United States

Methodist Physicians Clinic

Fremont, Nebraska, United States

Santa Rosa Medical Centers of Nevada

Las Vegas, Nevada, United States

Lucas Research, Inc.

Morehead City, North Carolina, United States

Centricity Research Columbus

Columbus, Ohio, United States

Olympus Family Medicine

Salt Lake City, Utah, United States

Manassas Clinical Research Center

Manassas, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07527650

Related Trials

A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus

NCT075994102 locations

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058163 locations

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

NCT07662109272 locations

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT0722811738 locations

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044149 locations